RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.
Stocks · News reference
NewAmsterdam Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Recommending Marketing Authorization For Ubeslo, Evlarco To Treat Primary Hypercholesterolemia
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 246.67 percent decrease over losses of $(0.15) per share
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51